Drug repurposing against SARS-CoV-2: A review based on principal reports
Keywords:
Coronavirus, Drug Therapy, RepurposingAbstract
Despite the measures taken and the molecular advances for the development of new agents for the control of SARS-CoV-2 infection, there is still insufficient development of an effective treatment. The objective of the review was to describe the clinical studies and reported articles on drugs used as possible therapeutic agents for COVID-19 and the main conclusions on their reuse. A non-systematic review through PubMed, ScienceDirect, and clinical trials at ClinicalTrials.gov on original articles and case report in English and Spanish that will report information on COVID-19 treatment and its main conclusions. Articles that were not relevant or that did not mention updated information to that reported in other articles were excluded. A total of 99 bibliographic references were included. COVID-19 appears as a multisystemic disease with variable clinical symptoms. Since no specific treatment is yet known, multiple drugs have been proposed that attack the different pathways of SARS-CoV-2. For severe disease in patients who require hospitalization and oxygen support, the use of remdesivir, dexamethasone, or tocilizumab is recommended if there are patient conditions that apply to use them. The use of ivermectin, colchicine, lopinavir/ritonavir, hydroxychloroquine, and chloroquine have not reported benefits that surpass adverse effects.
Downloads
References
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020; 6736(20):1–10.
Jin H, Hong C, Chen S, Zhou Y, Wang Y, Mao L, et al. Consensus for prevention and management of coronavirus disease 2019 (COVID-19) for neurologists. Stroke Vasc Neurol. 2020; 5(2):146–151.
Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respiratory Medicine. 2020; S2213-2600(20): 30079–5.
Yang W, Cao Q, Qin L, Wang X, Cheng Z, Pan A, et al. Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19): A multi-center study in Wenzhou city. Journal of Infection. 2020; 80(4):388–93.
Chen C, Zhang Y, Huang J, Yin P, Cheng Z, Wu J, et al. Favipiravir Versus Arbidol for Clinical Recovery Rate in Moderate and Severe Adult COVID-19 Patients: A Prospective, Multicenter, Open-Label, Randomized Controlled Clinical Trial. Front Pharmacol. 2021; 12:683296.
Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, et al. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. Engineering. 2020;
Reddy PK, Patil S, Khobragade A, Balki A, Raj A, Kalikar M, et al. Evaluation of the Safety and Efficacy of Favipiravir in Adult Indian Patients with Mild-to-Moderate COVID-19 in a Real-World Setting. Int J Gen Med. 2022; 15:4551–63.
Bosaeed M, Alharbi A, Mahmoud E, Alrehily S, Bahlaq M, Gaifer Z, et al. Efficacy of favipiravir in adults with mild COVID-19: a randomized, double-blind, multicentre, placebo-controlled clinical trial. Clinical Microbiology and Infection. 2022 Apr 1; 28(4):602–8.
Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the Treatment of Covid-19 — Preliminary Report. N Engl J Med. 2020;1–12.
Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. The Lancet. 2020; 395(10236):1569–78.
Ader F, Bouscambert-Duchamp M, Hites M, Peiffer-Smadja N, Poissy J, Belhadi D, et al. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. Lancet Infect Dis. 2022 Feb 1; 22(2):209–21.
Gottlieb RL, Vaca CE, Paredes R, Mera J, Webb BJ, Perez G, et al. Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients. New England Journal of Medicine. 2022 Jan 27; 386(4):305–15.
Hung IFN, Lung KC, Tso EYK, Liu R, Chung TWH, Chu MY, et al. Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. The Lancet. 2020; 395(10238):1695–704.
Huang YQ, Tang SQ, Xu XL, Zeng YM, He XQ, Li Y, et al. No Statistically Apparent Difference in Antiviral Effectiveness Observed Among Ribavirin Plus Interferon-Alpha, Lopinavir/Ritonavir Plus Interferon-Alpha, and Ribavirin Plus Lopinavir/Ritonavir Plus Interferon-Alpha in Patients with Mild to Moderate Coron. Front Pharmacol. 2020 Jul;11.
Tong S, Su Y, Yu Y, Wu C, Chen J, Wang S, et al. Ribavirin therapy for severe COVID-19: a retrospective cohort study. Int J Antimicrob Agents. 2020 Sep; 56(3):106114.
Ye XT, Luo YL, Xia SC, Sun QF, Ding JG, Zhou Y, et al. Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease 2019. Eur Rev Med Pharmacol Sci. 2020; 24(6):3390–6.
Rahmani H, Davoudi-Monfared E, Nourian A, Khalili H, Hajizadeh N, Jalalabadi NZ, et al. Interferon β-1b in treatment of severe COVID-19: A randomized clinical trial. Int Immunopharmacol. 2020; 88:106903.
Hassaniazad M, Farshidi H, Gharibzadeh A, Bazram A, Khalili E, Noormandi A, et al. Efficacy and safety of favipiravir plus interferon-beta versus lopinavir/ritonavir plus interferon-beta in moderately ill patients with COVID-19: A randomized clinical trial. J Med Virol. 2022 Jul 1; 94(7):3184–91.
Yang C, Ke C, Yue D, Li W, Hu Z, Liu W. Effectiveness of Arbidol for COVID-19 Prevention in Health Professionals. Frontier in Public Health. 2020; 8:1–6.
Xu P, Huang J, Fan Z, Huang W, Qi M, Lin X. Arbidol/IFN‐α2b therapy for patients with corona virus disease 2019: a retrospective multicenter cohort study. Microbes Infect. 2020;22:200–5.
Ramachandran R, Bhosale V, Reddy H, Atam V, Faridi MMA, Fatima J, et al. Phase III, Randomized, Double-blind, Placebo controlled trial of Efficacy, Safety and Tolerability of Antiviral drug Umifenovir vs Standard care of therapy in non-severe COVID-19 patients. International Journal of Infectious Diseases. 2022 Feb 1; 115:62–9.
Zhuravel S v., Khmelnitskiy OK, Burlaka OO, Gritsan AI, Goloshchekin BM, Kim S, et al. Nafamostat in hospitalized patients with moderate to severe COVID-19 pneumonia: a randomised Phase II clinical trial. EClinicalMedicine. 2021 Nov 1;41.
Quinn TM, Gaughan EE, Bruce A, Antonelli J, O’connor R, Li F, et al. Randomised controlled trial of intravenous nafamostat mesylate in COVID pneumonitis: Phase 1b/2a experimental study to investigate safety, Pharmacokinetics and Pharmacodynamics. EBioMedicine [Internet]. 2022; 76:103856. Available from: https://doi.org/10.1016/j.
Boulware DR, Pullen MF, Bangdiwala AS, Pastick KA, Lofgren SM, Okafor EC, et al. A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. N Engl J Med. 2020; 1–9.
Geleris J, Sun Y, Platt J, Zucker J, Baldwin M, Hripcsak G, et al. Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl J Med. 2020;382:2411–8.
Rosenberg ES, Dufort EM, Udo T, Wilberschied LA, Kumar J, Tesoriero J, et al. Association of Treatment with Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State. JAMA. 2020; 12203:1–10.
Arshad S, Kilgore P, Chaudhry ZS, Jacobsen G, Dee D, Huitsing K, et al. Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19. International Journal of Infectious Diseases. 2020; 97.
Lagier J christophe, Million M, Gautret P, Colson P, Cortaredona S, Giraud-Gatineau A, et al. Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis. Travel Med Infect Dis. 2020; 36:101791.
Catteau L, Dauby N, Montourcy M, Bottieau E, Hautekiet J, Goetghebeur E, et al. Low-dose hydroxychloroquine therapy and mortality in hospitalised patients with COVID-19: a nationwide observational study of 8075 participants. Int J Antimicrob Agents. 2020; 56(4):106144.
Lammers AJJ, Brohet RM, Theunissen REP, Koster C, Rood R, Verhagen DWM, et al. Early Hydroxychloroquine but not Chloroquine use reduces ICU admission in COVID-19 patients. International Journal of Infectious Diseases. 2020; 101:283–9.
Gentry CA, Humphrey MB, Thind SK, Hendrickson SC, Kurdgelashvili G, Ii RJW. Long-term hydroxychloroquine uses in patients with rheumatic conditions and development of SARS-CoV-2 infection: a retrospective cohort study. Lancet Rheumatol. 2020;9913(20):1–9.
Avezum Á, Oliveira GBF, Oliveira H, Lucchetta RC, Pereira VFA, Dabarian AL, et al. Hydroxychloroquine versus placebo in the treatment of non-hospitalised patients with COVID-19 (COPE – Coalition V): A double-blind, multicentre, randomised, controlled trial. The Lancet Regional Health – Americas [Internet]. 2022 Jul 1; 11:100243. Available from: https://doi.org/10.1016/j.lana.2022.100243
Sivapalan P, Ulrik CS, Lapperre TS, Bojesen RD, Eklöf J, Browatzki A, et al. Azithromycin and hydroxychloroquine in hospitalised patients with confirmed COVID-19: a randomised double-blinded placebo-controlled trial. European Respiratory Journal [Internet]. 2022; 59:2100752. Available from: http://dx.doi.org/10.1183/13993003.00752-2021
Biran N, Ip A, Ahn J, Go RC, Wang S, Mathura S, et al. Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study. Lancet Rheumatol. 2020 Aug; 2(10):e603–12.
Hermine O, Mariette X, Tharaux PL, Resche-Rigon M, Porcher R, Ravaud P. Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial. JAMA Intern Med. 2021 Jan; 181(1):32–40.
De Rossi N, Scarpazza C, Filippini C, Cordioli C, Rasia S, Mancinelli CR, et al. Early use of low dose tocilizumab in patients with COVID-19: A retrospective cohort study with a complete follow-up. EClinicalMedicine. 2020 Jul; 25:100459.
Hermine O, Mariette X, Tharaux PL, Resche-Rigon M, Porcher R, Ravaud P. Effect of Tocilizumab vs Usual Care in Adults Hospitalized with COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial. JAMA Intern Med. 2021;181(1):32–40.
Rosas IO, Bräu N, Waters M, Go RC, Malhotra A, Hunter BD, et al. Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA). EClinicalMedicine. 2022; 47:101409.
Ravikirti, Roy R, Pattadar C, Raj R, Agarwal N, Biswas B, et al. Evaluation of Ivermectin as a Potential Treatment for Mild to Moderate COVID-19: A Double-Blind Randomized Placebo Controlled Trial in Eastern India. J Pharm Pharm Sci. 2021; 24:343–50.
Mahmud R, Rahman MM, Alam I, Ahmed KGU, Kabir AKMH, Sayeed SKJB, et al. Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized trial. J Int Med Res. 2021 May;49(5):3000605211013550.
Rahman MA, Iqbal SA, Islam MA, Niaz MK, Hussain T, Siddiquee TH. Comparison of Viral Clearance between Ivermectin with Doxycycline and Hydroxychloroquine with Azithromycin in COVID-19 Patients. J Bangladesh Coll Phys Surg. 2020 Jun;5–9.
Vallejos J, Zoni R, Bangher M, Villamandos S, Bobadilla A, Plano F, et al. Ivermectin to prevent hospitalizations in patients with COVID-19 ( IVERCOR-COVID19 ) controlled trial. BMC Infect Dis. 2021; 21(1):635.
Buonfrate D, Chesini F, Martini D, Roncaglioni MC, Ojeda Fernández ML, Alvisi MF, et al. High-dose ivermectin for early treatment of COVID-19 (COVER study): a randomised, double-blind, multicentre, phase II, dose-finding, proof-of-concept clinical trial. Int J Antimicrob Agents [Internet]. 2022;59(2):106516. Available from: https://doi.org/10.1016/j.ijantimicag.2021.106516
Lim SCL, Hor CP, Tay KH, Jelani AM, Tan WH, Ker HB, et al. Efficacy of Ivermectin Treatment on Disease Progression Among Adults with Mild to Moderate COVID-19 and Comorbidities The I-TECH Randomized Clinical Trial. JAMA Intern Med. 2022;182(4):426–35.
Gordon CJ, Tchesnokov EP, Feng JY, Porter DP, Götte M. The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus. Journal of Biological Chemistry. 2020; 295(15):4773–9.
Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020; 30(3):269–71.
Ko W chien, Rolain J marc, Lee N yao, Chen P lin, Huang C tai. Arguments in favour of remdesivir for treating SARS-CoV-2 infections. Int J Antimicrob Agents. 2020; (Mar 6):105933.
Williamson BN, Feldmann F, Schwarz B, Meade-White K, Porter DP, Schulz J, et al. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2 Brandi. bioRxiv Preprint. 2020; Apr 22.
Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19. N Engl J Med. 2020 Jun; 382(24):2327–36.
Singh AK, Singh A, Singh R, Misra A. Remdesivir in COVID-19: A critical review of pharmacology, pre-clinical and clinical studies. Diabetes and Metabolic Syndrome: Clinical Research and Reviews. 2020 Jul;14(4):641–8.
Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020;382(19):1787–99.
Jin YH, Cai L, Cheng ZS, Cheng H, Deng T, Fan YP, et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil Med Res. 2020 Feb; 7(1):4.
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet. 2020; 395(10229):1054–62.
RECOVERY Collaborative Group. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2020 Oct; 396(10259):1345–52.
Denholm JT, Davis J, Paterson D, Roberts J, Morpeth S, Snelling T, et al. The Australasian COVID-19 Trial (ASCOT) to assess clinical outcomes in hospitalised patients with SARS-CoV-2 infection (COVID-19) treated with lopinavir/ritonavir and/or hydroxychloroquine compared to standard of care: A structured summary of a study prot. Trials. 2020; 21(1):646.
Yang C, Ke C, Yue D, Li W, Hu Z, Liu W, et al. Effectiveness of Arbidol for COVID-19 Prevention in Health Professionals. Front Public Health. 2020; 8:249.
Amani B, Amani B, Zareei S, Zareei M. Efficacy and safety of arbidol (umifenovir) in patients with COVID-19: A systematic review and meta-analysis. Immun Inflamm Dis. 2021 Dec; 9(4):1197–208.
Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. The Lancet. 2020;395(10229):1033–4.
Khiali S, Khani E, Entezari-Maleki T. A Comprehensive Review of Tocilizumab in COVID-19 Acute Respiratory Distress Syndrome. J Clin Pharmacol. 2020 Sep; 60(9):1131–46.
Zhang C, Wu Z, Li JW, Zhao H, Wang GQ. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. Int J Antimicrob Agents. 2020 May; 55(5):105954.
Capra R, De Rossi N, Mattioli F, Romanelli G, Scarpazza C, Sormani MP, et al. Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia. Eur J Intern Med. 2020 Jun;76:31–5.
Wei PF. Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia. Chin Med J (Engl). 2020;133(9):1087–95.
Yamamoto M, Matsuyama S, Li X, Takeda M, Kawaguchi Y, Inouea J ichiro, et al. Identification of nafamostat as a potent inhibitor of Middle East respiratory syndrome (MERS) corona virus S-mediated membrane fusion using the split protein-based cell-cell fusion assay. Antimicrob Agents Chemother. 2016;60(11):6532–9.
Osawa I, Okamoto K, Ikeda M, Otani A, Wakimoto Y, Yamashita M, et al. Dynamic changes in fibrinogen and D-dimer levels in COVID-19 patients on nafamostat mesylate. J Thromb Thrombolysis. 2020
U.S. National Library of Medicine. Clinical Efficacy of Nafamostat Mesylate for COVID-19 Pneumonia - Full Text View - ClinicalTrials. ClinicalTrials.gov. 2020.
Moon K, Hong KW, Bae IG. Treatment effect of nafamostat mesylate in patients with COVID-19 pneumonia: study protocol for a randomized controlled trial. Trials. 2021 Nov;22(1):832.
Rossignol JF. Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus. J Infect Public Health. 2016; 9:227–30.
Calderón JM, Zerón HM. Treatment with Hydroxychloroquine vs Hydroxychloroquine + Nitazoxanide in COVID-19 patients with risk factors for poor prognosis: A structured summary of a study protocol for a randomised controlled trial. Trials. 2020; 21(1):504.
Rocco PRM, Silva PL, Cruz FF, Melo-Junior MAC, Tierno PFGMM, Moura MA, et al. Early use of nitazoxanide in mild COVID-19 disease: randomised, placebo-controlled trial. Eur Respir J. 2021 Jul; 58(1).
Sinha N, Balayla G. Hydroxychloroquine and covid-19. Postgrad Med J. 2020;96(1139):550–5.
Altalhi TA, Alswat K, Alsanie WF, Ibrahim MM, Aldalbahi A, El-Sheshtawy HS. Chloroquine and hydroxychloroquine inhibitors for COVID-19 sialic acid cellular receptor: Structure, hirshfeld atomic charge analysis and solvent effect. Journal of Molecular Sctructure. 2020; 1228:129459.
Touret F, Lamballerie X De. Of chloroquine and COVID-19. Antiviral Res. 2020;177:104762.
Furtado RHM, Berwanger O, Fonseca HA, Corrêa TD, Ferraz LR, Lapa MG, et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. The Lancet. 2020; 396(10256):P959-967.
Nicolò M, Ferro Desideri L, Bassetti M, Traverso CE. Hydroxychloroquine and chloroquine retinal safety concerns during COVID-19 outbreak. Int Ophthalmol. 2021 Feb;41(2):719–25.
Mastrangeli R, Palinsky W, Bierau H. How unique is interferon-β within the type I interferon family? Cytokine. 2018; 111:206–8.
Li S, Gong M, Zhao F, Shao J, Xie Y, Zhang Y, et al. Type I Interferons: Distinct Biological Activities and Current Applications for Viral Infection. Cellular Physiology and Biochemistry. 2018;51(5):2377–96.
Holder PG, Lim SA, Huang CS, Sharma P, Dagdas YS, Bulutoglu B, et al. Engineering interferons and interleukins for cancer immunotherapy. Adv Drug Deliv Rev. 2022; 182:114112.
Georgel P. Crosstalk between Interleukin-1β and Type I Interferons Signaling in Autoinflammatory Diseases. Cells. 2021;10(5):1134.
Bewersdorf JP, Giri S, Wang R, Podoltsev N, Williams RT, Rampal RK, et al. Interferon Therapy in Myelofibrosis: Systematic Review and Meta-analysis. Clin Lymphoma Myeloma Leuk. 2020;20(10):e712–23.
Falzarano D, De Wit E, Rasmussen AL, Feldmann F, Okumura A, Scott DP, et al. Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nat Med. 2013;19(10):1313–7.
Chung RT, Jr MG, Polyak SJ, Lemon SM, Jake T, Hoofnagle JH. Mechanisms of Action of Interferon and Ribavirin in Chronic Hepatitis C: Summary of a Workshop. Hepatology. 2008;47(1):306–320.
Zorzitto J, Galligan CL, Ueng JJM, Fish EN. Characterization of the antiviral effects of interferon- a against a SARS-like coronoavirus infection in vitro. Cell Res. 2006;16:220–9.
Wang L, Xu X, Ruan J, Lin S, Jiang J, Ye H. Quadruple therapy for asymptomatic COVID-19 infection patients. Expert Rev Anti Infect Ther. 2020; 18(7):617–24.
Hao S rui, Yan R, Zhang S yan, Lian J shan, Cai H, Zhang X li, et al. Interferon-α2b spray inhalation did not shorten virus shedding time of SARS-CoV-2 in hospitalized patients: a preliminary matched case-control study. J Zhejiang Univ Sci B. 2020; 21(8):628–36.
Wang N, Zhan Y, Zhu L, Hou Z, Liu F, Song P, et al. Retrospective Multicenter Cohort Study Shows Early Interferon Therapy Is Associated with Favorable Clinical Responses in COVID-19 Patients. Cell Host Microbe. 2020; 28(3):455-464.e2.
Arabi YM, Asiri AY, Assiri AM, Balkhy HH, Al Bshabshe A, Al Jeraisy M, et al. Interferon Beta-1b and Lopinavir–Ritonavir for Middle East Respiratory Syndrome. New England Journal of Medicine. 2020; 1–12.
Arabi YM, Asiri AY, Assiri AM, Aziz Jokhdar HA, Alothman A, Balkhy HH, et al. Treatment of Middle East respiratory syndrome with a combination of lopinavir/ritonavir and interferon-β1b (MIRACLE trial): statistical analysis plan for a recursive two-stage group sequential randomized controlled trial. Trials. 2020; 21(1):8.
Mozafari N, Saffaei A, Alizadeh M, Shabani M. Cutaneous necrotic lesion: A wonderful delay adverse effect of interferon beta-1b injection for multiple sclerosis treatment. J Cosmet Dermatol. 2020; 19(4):951–3.
Davoudi-Monfared E, Rahmani H, Khalili H, Hajiabdolbaghi M, Salehi M, Abbasian L, et al. A randomized clinical trial of the efficacy and safety of interferon β-1a in treatment of severe COVID-19. Antimicrob Agents Chemother. 2020;64(9):1–14.
Akamatsu MA, de Castro JT, Takano CY, Ho PL. Off balance: Interferons in COVID-19 lung infections. EBioMedicine. 2021 Nov; 73:103642.
Pinto D, Park YJ, Beltramello M, Walls AC, Tortorici MA, Bianchi S, et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature. 2020;583(7815):290–5.
Gupta A, González-Rojas Y, Juárez E, Crespo Casal M, Moya J, Falci DR, et al. Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab. New England Journal of Medicine. 2021; 385(21):1941–50.
Dolgin E. “Super-antibodies” could curb COVID-19 and help avert future pandemics. Vol. 39, Nature biotechnology. 2021. p. 783–5.
Noreen S, Maqbool I, Madni A. Dexamethasone: Therapeutic potential, risks, and future projection during COVID-19 pandemic. Eur J Pharmacol. 2021 Mar; 894:173854.
Ranjbar K, Moghadami M, Mirahmadizadeh A, Fallahi MJ, Khaloo V, Shahriarirad R, et al. Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: a triple-blinded randomized controlled trial. BMC Infect Dis. 2021 Apr;21(1):337.
Pinzón MA, Ortiz S, Holguín H, Betancur JF, Cardona Arango D, Laniado H, et al. Dexamethasone vs methylprednisolone high dose for Covid-19 pneumonia. PLoS One. 2021;16(5):e0252057.
Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et al. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2021 Feb;384(8):693–704.
Messina V, Nevola R, Izzi A, de Lucia Sposito P, Marrone A, Rega R, et al. Efficacy and safety of the sofosbuvir/velpatasvir combination for the treatment of patients with early mild to moderate COVID-19. Sci Rep. 2022 Dec 1;12(1).
Sayad B, Khodarahmi R, Najafi F, Miladi R, Mohseni Afshar Z, Mansouri F, et al. Efficacy and safety of sofosbuvir/velpatasvir versus the standard of care in adults hospitalized with COVID-19: A single-centre, randomized controlled trial. Journal of Antimicrobial Chemotherapy. 2021 Aug 1; 76(8):2158–67.
Johnson MG, Puenpatom A, Moncada PA, Burgess L, Duke ER, Ohmagari N, et al. Effect of Molnupiravir on Biomarkers, Respiratory Interventions, and Medical Services in COVID-19: A Randomized, Placebo-Controlled Trial. Ann Intern Med. 2022 Aug; 175(8):1126–34.
Jayk Bernal A, Gomes da Silva MM, Musungaie DB, Kovalchuk E, Gonzalez A, Delos Reyes V, et al. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. N Engl J Med. 2022 Feb; 386(6):509–20.
Paxlovid for treatment of COVID-19. Med Lett Drugs Ther. 2022 Jan;64(1642):9–10.
Dawood AA. The efficacy of Paxlovid against COVID-19 is the result of the tight molecular docking between Mpro and antiviral drugs (nirmatrelvir and ritonavir). Adv Med Sci [Internet]. 2022 Mar [cited 2022 Nov 17]; 68(1):1–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/36368287%0Ahttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC9626444
Hung YP, Lee JC, Chiu CW, Lee CC, Tsai PJ, Hsu IL, et al. Oral Nirmatrelvir/Ritonavir Therapy for COVID-19: The Dawn in the Dark? Antibiotics [Internet]. 2022 Feb 1 [cited 2022 Nov 17]; 11(2). Available from: /pmc/articles/PMC8868411/
Owen DR, Allerton CMN, Anderson AS, Aschenbrenner L, Avery M, Berritt S, et al. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19. Science (1979) [Internet]. 2021 Dec 24 [cited 2022 Nov 17]; 374(6575):1586–93. Available from: https://www.science.org/doi/10.1126/science.abl4784
Mahase E. Covid-19: Pfizer’s paxlovid is 89% effective in patients at risk of serious illness, company reports. BMJ [Internet]. 2021 Nov 8; n2713. Available from: https://www.bmj.com/lookup/doi/10.1136/bmj.n2713
Najjar-Debbiny R, Gronich N, Weber G, Khoury J, Amar M, Stein N, et al. Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients. Clinical Infectious Diseases [Internet]. 2022 Jun 2 [cited 2022 Nov 17]; Available from: /pmc/articles/PMC9214014/
Wang L, Berger NA, Davis PB, Kaelber DC, Volkow ND, Xu R. COVID-19 rebound after Paxlovid and Molnupiravir during January-June 2022. medRxiv [Internet]. 2022 Jun 22 [cited 2022 Nov 17]; Available from: /pmc/articles/PMC9258292/
Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, et al. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. New England Journal of Medicine [Internet]. 2022 Apr 14 [cited 2022 Nov 17];386(15):1397–408. Available from: /pmc/articles/PMC8908851/
Marzolini C, Kuritzkes DR, Marra F, Boyle A, Gibbons S, Flexner C, et al. Recommendations for the Management of Drug–Drug Interactions Between the COVID-19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications [Internet]. Clinical Pharmacology and Therapeutics. Wiley-Blackwell; 2022 [cited 2022 Nov 17]. Available from: /pmc/articles/PMC9348462/
An eua for bamlanivimab and etesevimab for covid-19. Medical Letter on Drugs and Therapeutics [Internet]. 2021;63(1621):49–51. Available from: https://secure.medicalletter.org/TML-article-1621a
Razonable RR, O’Horo JC, Challener DW, Arndt L, Arndt RF, Clune CG, et al. Curbing the Delta Surge: Clinical Outcomes After Treatment with Bamlanivimab-Etesevimab, Casirivimab-Imdevimab, or Sotrovimab for Mild to Moderate Coronavirus Disease 2019. Mayo Clin Proc [Internet]. 2022 Sep 1 [cited 2022 Nov 17]; 97(9):1641–8. Available from: /pmc/articles/PMC9222650/
Chen P, Behre G, Hebert C, Kumar P, Farmer MacPherson L, Graham-Clarke PL, et al. Bamlanivimab and Etesevimab Improve Symptoms and Associated Outcomes in Ambulatory Patients at Increased Risk for Severe Coronavirus Disease 2019: Results from the Placebo-Controlled Double-Blind Phase 3 BLAZE-1 Trial. Open Forum Infect Dis [Internet]. 2022 May 1 [cited 2022 Nov 18];9(5). Available from: /pmc/articles/PMC9045956/
O’Horo J, Challener DW, Anderson RJ, Arndt RF, Ausman SE, Hall ST, et al. Rates of Severe Outcomes After Bamlanivimab-Etesevimab and Casirivimab-Imdevimab Treatment of High-Risk Patients with Mild to Moderate Coronavirus Disease 2019. Mayo Clin Proc [Internet]. 2022 May 1 [cited 2022 Nov 18]; 97(5):943–50. Available from: /pmc/articles/PMC8864104/
Almagro JC, Mellado-Sánchez G, Pedraza-Escalona M, Pérez-Tapia SM. Evolution of Anti-SARS-CoV-2 Therapeutic Antibodies [Internet]. Vol. 23, International Journal of Molecular Sciences. Multidisciplinary Digital Publishing Institute (MDPI); 2022 [cited 2022 Nov 17]. Available from: /pmc/articles/PMC9456190/
Monday LM, Brar I, Alangaden G, Ramesh MS. SARS-CoV-2 neutralizing antibodies for COVID-19: Outcomes for bamlanivimab versus bamlanivimab-etesevimab combination in a racially diverse cohort of patients with significant comorbidities. J Clin Pharm Ther [Internet]. 2022 Sep 1 [cited 2022 Nov 17];47(9):1438–43. Available from: /pmc/articles/PMC9348308/
National Institutes of Health. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. NIH. 2020;4–238.
Reis G, Silva EASM, Silva DCM, Thabane L, Milagres AC, Ferreira TS, et al. Effect of Early Treatment with Ivermectin among Patients with Covid-19. New England Journal of Medicine. 2022;386(18):1721–31.
El Sayed RG, Hafez AF, Mohammed Haggag AMA, Alhadidy MA. Effect of combined use of ivermectin and colchicine in COVID-19 patients. Egypt J Anaesth. 2022 Dec 31;38(1):365–72.
Lopes MI, Bonjorno LP, Giannini MC, Amaral NB, Menezes PI, Dib SM, et al. Beneficial effects of colchicine for moderate to severe COVID-19: A randomised, double-blinded, placebo-controlled clinical trial. RMD Open. 2021;7(1):e001455.
Schwartz I, Boesen ME, Cerchiaro G, Doram C, Edwards BD, Ganesh A, et al. Assessing the efficacy and safety of hydroxychloroquine as outpatient treatment of COVID-19: a randomized controlled trial. CMAJ Open. 2021;9(2):E693–702.
Gaibani P, Tonetti T, Bartoletti M, Re MC, Viale P, Ranieri VM. Antiviral activity of interferon-based combination therapy in critically ill patients with COVID-19: Preliminary observations. Vol. 24, Journal of global antimicrobial resistance. 2021. p. 124–6.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 AVFT – Archivos Venezolanos de Farmacología y Terapéutica
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
